StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) stock

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.84−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $615.80MP/E –Yield –

Design Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Design Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$79.36M. For fiscal 2025 it was -$79.47M. The highest annual figure on record is -$8.33M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$79.47M–
FY2024Dec 31, 2024-$62.38M–
FY2023Dec 31, 2023-$78.19M–
FY2022Dec 31, 2022-$67.59M–
FY2021Dec 31, 2021-$35.83M–
FY2020Dec 31, 2020-$8.33M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.18M–
Q1 FY2026Mar 31, 2026-$19.71M–
Q4 FY2025Dec 31, 2025-$18.17M–
Q3 FY2025Sep 30, 2025-$19.31M–
Q2 FY2025Jun 30, 2025-$21.57M–
Q1 FY2025Mar 31, 2025-$20.42M–
Q4 FY2024Dec 31, 2024-$16.69M–
Q3 FY2024Sep 30, 2024-$16.25M–
Q2 FY2024Jun 30, 2024-$15.04M–
Q1 FY2024Mar 31, 2024-$14.40M–
Q4 FY2023Dec 31, 2023-$15.12M–
Q3 FY2023Sep 30, 2023-$18.82M–
Q2 FY2023Jun 30, 2023-$22.60M–
Q1 FY2023Mar 31, 2023-$21.65M–
Q4 FY2022Dec 31, 2022-$19.39M–
Q3 FY2022Sep 30, 2022-$19.19M–
Q2 FY2022Jun 30, 2022-$15.64M–
Q1 FY2022Mar 31, 2022-$13.37M–
Q4 FY2021Dec 31, 2021-$11.13M–
Q3 FY2021Sep 30, 2021-$11.34M–
Q2 FY2021Jun 30, 2021-$7.69M–
Q1 FY2021Mar 31, 2021-$5.68M–
Q4 FY2020Dec 31, 2020-$3.86M–
Q3 FY2020Sep 30, 2020-$2.38M–
Q2 FY2020Jun 30, 2020-$1.46M–
Q1 FY2020Mar 31, 2020-$623.00K–

More Design Therapeutics figures

See a number that looks wrong?